PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1351280
PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1351280
GCC Erectile Dysfunction Drugs Market, By Product (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros, Others); By Distribution Channel ; By Country, Trend Analysis, Competitive Landscape & Forecast, 2019-2029
GCC Erectile Dysfunction Drugs Market Size Set to Grow at CAGR of 9% to Reach USD 115.32 Million by 2029.
GCC erectile dysfunction drugs market is gaining traction because of the rising prevalence of erectile dysfunction caused by poor lifestyle choices.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the GCC erectile dysfunction drugs market size at USD 68.83 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the GCC erectile dysfunction drugs market size to grow at a CAGR of 8.98% reaching a value of USD 115.32 million by 2029. The GCC erectile dysfunction drugs market is expected to grow mainly due to increased erectile dysfunction prevalence brought on by the poor lifestyle choices made by the male population as well as greater knowledge and acceptance of the condition and its treatment.
GCC Erectile Dysfunction Drugs Market - Overview:
According to Mayo Clinic, erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. ED can have a variety of reasons and can signal underlying health issues including diabetes, high cholesterol, or other conditions like heart disease. Drugs used to treat ED work by boosting blood flow to the penis, which aids in achieving and maintaining an erection. The most often recommended treatments for ED are sildenafil (Viagra) and tadalafil (Cialis), which also have favorable clinical outcomes.
GCC Erectile Dysfunction Drugs Market
Segmental Information:
GCC Erectile Dysfunction Drugs Market - By Product:
Based on product, the GCC erectile dysfunction drugs market is divided into Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), and others. Viagra (sildenafil citrate) holds the highest share of the GCC erectile dysfunction drugs market by product. Viagra boosts blood flow to the penis when sexually stimulated and assists in maintaining an erection by relaxing a few smooth muscles. As a result, pharmaceutical companies are launching generic sildenafil citrate pills in the market to tap into the growing market opportunities, propelling the overall market growth.
Impact of COVID-19 on GCC Erectile Dysfunction Drugs Market
The unprecedented COVID-19 pandemic presented new growth opportunities for the GCC dysfunction drugs market. Several studies revealed that the COVID-19 infection caused a 20% increase in the prevalence of erectile dysfunction among men. According to an article published in the International Journal of Impotence Research, the psychological burden of the COVID-19 infection and direct testicular damage influenced the chances of ED among men during the pandemic. As a result, the demand for erectile dysfunction drugs spiked in the GCC countries during the pandemic, increasing the overall market growth.
Competitive Landscape:
Major players operating in the GCC erectile dysfunction drugs market include: Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, and Bayer AG.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and the GCC Erectile Dysfunction Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the GCC Erectile Dysfunction Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
2. Executive Summary
3. GCC Erectile Dysfunction Drugs Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Growth in Embracing Poor Lifestyle Choices
- 3.2.1.2. Increasing Incidence of Diseases
- 3.2.1.3. Rising Prevalence of Erectile Dysfunction
- 3.2.2. Restraints
- 3.2.2.1. Negative Side Effects of Erectile Dysfunction Drugs
- 3.2.2.2. Low Awareness associated with Erectile Dysfunction Drugs
- 3.2.2. Opportunities
- 3.2.2.1. Increased Pharmaceutical Manufacturing
- 3.2.2.2. Increasing Investments in R&D and Clinical Trials
- 3.2.4. Challenges
- 3.2.4.1. Increasing Availability of Counterfeit Erectile Dysfunction Medicines
- 3.2.1. Growth Drivers
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
4. GCC Erectile Dysfunction Drugs Market Overview
- 4.1. Market Size & Forecast, 2019-2029
- 4.1.1. By Value (USD Million)
- 4.2. Market Share and Forecast
- 4.2.1. By Product
- 4.2.1.1. Viagra (sildenafil citrate)
- 4.2.1.2. Cialis (tadalafil)
- 4.2.1.3. Levitra/Staxyn (vardenafil)
- 4.2.1.4. Stendra/Spedra (avanafil)
- 4.2.1.5. Zydena (udenafil)
- 4.2.1.6. Vitaros (alprostadil cream)
- 4.2.1.7. Other
- 4.2.2. By Distribution Channel
- 4.2.2.1. Hospital Pharmacies
- 4.2.2.2. Retail Pharmacies
- 4.2.2.3. Online Pharmacies
- 4.2.3. By Country
- 4.2.3.1. Bahrain
- 4.2.3.2. Kuwait
- 4.2.3.3. Oman
- 4.2.3.4. Qatar
- 4.2.3.5. Saudi Arabia
- 4.2.3.6. United Arab Emirates
- 4.2.1. By Product
5. Bahrain Erectile Dysfunction Drugs Market
- 5.1. Market Size & Forecast, 2019-2029
- 5.1.1. By Value (USD Million)
- 5.2. Market Share & Forecast
- 5.2.1. By Product
- 5.2.2. By Distribution Channel
- 5.2.3. By End User
- 5.2.4. By Technique
6. Kuwait Erectile Dysfunction Drugs Market
- 6.1. Market Size & Forecast, 2019-2029
- 6.1.1. By Value (USD Million)
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Distribution Channel
7. Oman Erectile Dysfunction Drugs Market
- 7.1. Market Size & Forecast, 2019-2029
- 7.1.1. By Value (USD Million)
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Distribution Channel
8. Qatar Erectile Dysfunction Drugs Market
- 8.1. Market Size & Forecast, 2019-2029
- 8.1.1. By Value (USD Million)
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Distribution Channel
9. Saudi Arabia Erectile Dysfunction Drugs Market
- 9.1. Market Size & Forecast, 2019-2029
- 9.1.1. By Value (USD Million)
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Distribution Channel
10. United Arab Emirates Erectile Dysfunction Drugs Market
- 10.1. Market Size & Forecast, 2019-2029
- 10.1.1. By Value (USD Million)
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Distribution Channel
11. Competitive Landscape
- 11.1. List of Key Players and Their Offerings
- 11.2. GCC Erectile Dysfunction Drugs Market Share Analysis, 2022
- 11.3. Competitive Benchmarking, By Operating Parameters
- 11.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
12. Impact of Covid-19 on GCC Erectile Dysfunction Drugs Market
13. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- 13.1. Pfizer
- 13.2. Eli Lilly and Company
- 13.3. Teva
- 13.4. Sun Pharmaceutical
- 13.5. Lupin Limited
- 13.6. Glenmark Pharmaceuticals Limited
- 13.7. Cipla Ltd
- 13.8. Sanofi
- 13.9. Apricus Biosciences
- 13.10. Bayer AG
- 13.11. Other Prominent Players
14. Key Strategic Recommendations
15. Research Methodology
- 15.1. Qualitative Research
- 15.1.1. Primary & Secondary Research
- 15.2. Quantitative Research
- 15.3. Market Breakdown & Data Triangulation
- 15.3.1. Secondary Research
- 15.3.2. Primary Research
- 15.4. Breakdown of Primary Research Respondents, By Country
- 15.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
- Figure 1: GCC Erectile Dysfunction Drugs Market Segmentation
- Figure 2: GCC Erectile Dysfunction Drugs Market Value Chain Analysis
- Figure 3: Company Market Share Analysis, 2022
- Figure 4: GCC Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 5: GCC Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 6: GCC Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 7: GCC Erectile Dysfunction Drugs Market Share, By Country, By Value, 2019-2029
- Figure 8: Bahrain Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 9: Bahrain Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 10: Bahrain Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 11: Kuwait Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 12: Kuwait Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 13: Kuwait Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 14: Oman Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 15: Oman Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 16: Oman Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 17: Qatar Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 18: Qatar Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 19: Qatar Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 20: Saudi Arabia Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 21: Saudi Arabia Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 22: Saudi Arabia Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Figure 23: United Arab Emirates Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Figure 24: United Arab Emirates Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Figure 25: United Arab Emirates Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
List of Tables
- Table 1: GCC Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 2: GCC Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 3: GCC Erectile Dysfunction Drugs Market Size, By Country, By Value, 2019-2029
- Table 4: Bahrain Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 5: Bahrain Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 6: Kuwait Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 7: Kuwait Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 8: Oman Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 9: Oman Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 10: Qatar Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 11: Qatar Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 12: Saudi Arabia Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019-2029
- Table 13: Saudi Arabia Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019-2029
- Table 14: United Arab Emirates Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019-2029
- Table 15: United Arab Emirates Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019-2029
- Table 16: United Arab Emirates Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019-2029
- Table 17: Pfizer Company Overview
- Table 18: Pfizer Financial Overview
- Table 19: Eli Lilly and Company: Company Overview
- Table 20: Eli Lilly and Company Financial Overview
- Table 21: Teva Company Overview
- Table 22: Teva Financial Overview
- Table 23: Sun Pharmaceutical Company Overview
- Table 24: Sun Pharmaceutical Financial Overview
- Table 25: Lupin Limited Company Overview
- Table 26: Lupin Limited Financial Overview
- Table 27: Glenmark Pharmaceuticals Limited Company Overview
- Table 28: Glenmark Pharmaceuticals Limited Financial Overview
- Table 29: Cipla Ltd Company Overview
- Table 30: Cipla Ltd Financial Overview
- Table 31: Sanofi Company Overview
- Table 32: Sanofi Financial Overview
- Table 33: Apricus Biosciences Company Overview
- Table 34: Apricus Biosciences Financial Overview
- Table 35: Bayer AG Company Overview
- Table 36: Bayer AG Financial Overview
